Franco-Nevada (FNV) Earnings Beat Estimates in Q1, View Up Zacks.com 7 hrs ago
Franco-Nevada Corporation FNV reported adjusted earnings of 84 cents per share in first-quarter 2021, up 47% from the prior-year quarter. Additionally, the bottom line surpassed the Zacks Consensus Estimate of 79 cents.
Popular Searches
The company generated revenues of $309 million in the reported quarter, reflecting year-over-year growth of 28%. The top-line figure, however, missed the Zacks Consensus Estimate of $313 million. In the March-end quarter, 85.4% of revenues were sourced from gold and gold equivalents (61.6% gold, 15.4% silver, 6.3% platinum group metals and 2.1% from other mining assets).
The company sold 149,575 Gold Equivalent Ounces (GEOs) in the reported quarter, up from the prior-year quarter’s 134,941 GEOs. Higher contributions from the Hemlo, Cobre Panama, Antapaccay and Antamina mines were partly offset by lower contributions from Sudbury and Guadalupe-Palmarejo.
Copa Holdings (CPA) came out with a quarterly loss of $2.23 per share versus the Zacks Consensus Estimate of a loss of $2.25. This compares to earnings of $1.75 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 0.89%. A quarter ago, it was expected that this holding company for Panama's national airline would post a loss of $1.90 per share when it actually produced.
10x Genomics (TXG) Reports Q1 Loss, Tops Revenue Estimates yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
SLR Investment (SLRC) delivered earnings and revenue surprises of 2.78% and 1.40%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Nu Skin (NUS) Stock Gains on Q1 Earnings Beat & Raised View Zacks.com 9 hrs ago
Shares of
Nu Skin Enterprises, Inc. NUS rose 4.7% in the after-market trading session on May 5, as it delivered impressive first-quarter 2021 results. Notably, the top and the bottom line increased year over year as well as beat the Zacks Consensus Estimate. Moreover, management raised its 2021 revenues and earnings view.
The company is encouraged about its recent innovations like ageLOC Boost and Nutricentials Bioadaptives. Moreover, it is optimistic about strong demand for new product introductions that are lined during the back half of 2021. These include Beauty Focus Collagen+, ageLOC Meta and a key Pharmanex product introduction. Further, the company continued to see solid momentum in the West markets, with robust adoption in social commerce business model.